Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05668962 · ClinicalTrials.gov registry record · Phase 2

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

A Phase 2 study of Thyroid Cancer and Papillary Thyroid Cancer, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
6
Study locations

NCT05668962 is a Phase 2 study of Thyroid Cancer and Papillary Thyroid Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05668962, a Phase 2 study of Thyroid Cancer and Papillary Thyroid Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
6
Study locations

Study Summary

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).

Conditions Studied

Thyroid Cancer Papillary Thyroid Cancer Unresectable Thyroid Gland Carcinoma Thyroid Carcinoma Follicular Thyroid Cancer Metastatic Thyroid Cancer

Interventions

  • DRUG Selpercatinib
  • DRUG Sodium Iodine I-131
  • DRUG rhTSH

Study Locations (6)

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • University of Michigan - Ann Arbor

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-03-01
Est. Completion 2026-01-01
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05668962

The ClinicalTrials.gov registry entry for NCT05668962 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Selpercatinib is the first listed.

NCT05668962 reports 6 study locations spanning 6 distinct geographic areas - top geographies include District of Columbia, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05668962 about?

NCT05668962 is a clinical study titled "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC". This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination wi...

What is the current status of trial NCT05668962?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-03-01. Estimated completion is 2026-01-01.

What conditions does trial NCT05668962 study?

This clinical trial studies the following conditions: Thyroid Cancer, Papillary Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Thyroid Carcinoma, Follicular Thyroid Cancer.

What interventions are being tested in trial NCT05668962?

The interventions under investigation include: Selpercatinib (DRUG), Sodium Iodine I-131 (DRUG), rhTSH (DRUG).

Who is sponsoring clinical trial NCT05668962?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05668962 being conducted?

This trial has 6 study locations across District of Columbia, Florida, Massachusetts, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Cancer

All registered trials for this condition

Papillary Thyroid Cancer

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.